HC Wainwright Trims Gain Therapeutics (NASDAQ:GANX) Target Price to $8.00
Gain Therapeutics (NASDAQ:GANX – Free Report) had its price target trimmed by HC Wainwright from $9.00 to $8.00 in a research report released on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other research firms have also recently commented on GANX. Oppenheimer reiterated an outperform rating and […]
More Stories
CME Group (NASDAQ:CME) Rating Reiterated by Royal Bank of Canada
Royal Bank of Canada restated their sector perform rating on shares of CME Group (NASDAQ:CME – Free Report) in a...
Critical Comparison: Amplify Energy (NYSE:AMPY) & Sable Offshore (NYSE:SOC)
Amplify Energy (NYSE:AMPY – Get Free Report) and Sable Offshore (NYSE:SOC – Get Free Report) are both small-cap energy companies,...
Zurn Elkay Water Solutions Co. (NYSE:ZWS) Given Consensus Rating of “Hold” by Analysts
Zurn Elkay Water Solutions Co. (NYSE:ZWS – Get Free Report) has received a consensus recommendation of “Hold” from the seven...
Critical Comparison: Prothena (NASDAQ:PRTA) vs. Sonnet BioTherapeutics (NASDAQ:SONN)
Prothena (NASDAQ:PRTA – Get Free Report) and Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) are both small-cap medical companies, but...
Reviewing Root (NASDAQ:ROOT) and Universal Insurance (NYSE:UVE)
Root (NASDAQ:ROOT – Get Free Report) and Universal Insurance (NYSE:UVE – Get Free Report) are both small-cap finance companies, but...
First National Financial Co. (TSE:FN) Receives Consensus Recommendation of “Hold” from Analysts
First National Financial Co. (TSE:FN – Get Free Report) has been given a consensus rating of “Hold” by the six...